We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
For the quarter ended March 2024, Biogen Inc. (BIIB - Free Report) reported revenue of $2.29 billion, down 7% over the same period last year. EPS came in at $3.67, compared to $3.40 in the year-ago quarter.
The reported revenue represents a surprise of -1.09% over the Zacks Consensus Estimate of $2.32 billion. With the consensus EPS estimate being $3.45, the EPS surprise was +6.38%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Product- Multiple Sclerosis- Tecfidera- Rest of world: $210.60 million compared to the $172.03 million average estimate based on 21 analysts. The reported number represents a change of +5.4% year over year.
Revenue- Product- Spinal Muscular Atrophy- Spinraza- Rest of World: $192.80 million compared to the $277.93 million average estimate based on 21 analysts. The reported number represents a change of -35% year over year.
Revenue- Product- Spinal Muscular Atrophy- Spinraza- United States: $148.50 million compared to the $150.83 million average estimate based on 21 analysts. The reported number represents a change of +1.2% year over year.
Revenue- Product- Multiple Sclerosis- Tecfidera- United States: $43.70 million versus $51.79 million estimated by 21 analysts on average. Compared to the year-ago quarter, this number represents a -41.5% change.
Revenue- Product- Multiple Sclerosis- Tysabri- Total: $431.30 million versus the 24-analyst average estimate of $433.75 million. The reported number represents a year-over-year change of -8.8%.
Revenue- Contract manufacturing, royalty and other revenue: $184.60 million compared to the $141.62 million average estimate based on 24 analysts.
Revenue- Anti-CD20 Therapeutic Programs: $394 million versus the 24-analyst average estimate of $420.22 million. The reported number represents a year-over-year change of -1.4%.
Revenue- Product- Spinal Muscular Atrophy- Spinraza- Total: $341.30 million versus $421.22 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a -23% change.
Revenue- Product- Rare Disease- Total SKYCLARYS: $78 million versus $69.20 million estimated by 23 analysts on average.
Revenue- Product- Multiple Sclerosis- Fampyra- Total: $19.20 million versus the 23-analyst average estimate of $19.87 million. The reported number represents a year-over-year change of -20.3%.
Revenue- Product- Multiple Sclerosis- Fumarate- Tecfidera- Total: $254.30 million versus $223.95 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a -7.4% change.
Revenue- Product- Biosimilars- Total: $196.90 million versus $191.45 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.
Shares of Biogen have returned -8.9% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended March 2024, Biogen Inc. (BIIB - Free Report) reported revenue of $2.29 billion, down 7% over the same period last year. EPS came in at $3.67, compared to $3.40 in the year-ago quarter.
The reported revenue represents a surprise of -1.09% over the Zacks Consensus Estimate of $2.32 billion. With the consensus EPS estimate being $3.45, the EPS surprise was +6.38%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product- Multiple Sclerosis- Tecfidera- Rest of world: $210.60 million compared to the $172.03 million average estimate based on 21 analysts. The reported number represents a change of +5.4% year over year.
- Revenue- Product- Spinal Muscular Atrophy- Spinraza- Rest of World: $192.80 million compared to the $277.93 million average estimate based on 21 analysts. The reported number represents a change of -35% year over year.
- Revenue- Product- Spinal Muscular Atrophy- Spinraza- United States: $148.50 million compared to the $150.83 million average estimate based on 21 analysts. The reported number represents a change of +1.2% year over year.
- Revenue- Product- Multiple Sclerosis- Tecfidera- United States: $43.70 million versus $51.79 million estimated by 21 analysts on average. Compared to the year-ago quarter, this number represents a -41.5% change.
- Revenue- Product- Multiple Sclerosis- Tysabri- Total: $431.30 million versus the 24-analyst average estimate of $433.75 million. The reported number represents a year-over-year change of -8.8%.
- Revenue- Contract manufacturing, royalty and other revenue: $184.60 million compared to the $141.62 million average estimate based on 24 analysts.
- Revenue- Anti-CD20 Therapeutic Programs: $394 million versus the 24-analyst average estimate of $420.22 million. The reported number represents a year-over-year change of -1.4%.
- Revenue- Product- Spinal Muscular Atrophy- Spinraza- Total: $341.30 million versus $421.22 million estimated by 24 analysts on average. Compared to the year-ago quarter, this number represents a -23% change.
- Revenue- Product- Rare Disease- Total SKYCLARYS: $78 million versus $69.20 million estimated by 23 analysts on average.
- Revenue- Product- Multiple Sclerosis- Fampyra- Total: $19.20 million versus the 23-analyst average estimate of $19.87 million. The reported number represents a year-over-year change of -20.3%.
- Revenue- Product- Multiple Sclerosis- Fumarate- Tecfidera- Total: $254.30 million versus $223.95 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a -7.4% change.
- Revenue- Product- Biosimilars- Total: $196.90 million versus $191.45 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.
View all Key Company Metrics for Biogen here>>>Shares of Biogen have returned -8.9% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.